Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: Comparisons with insulin and insulin-like growth factor

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 10, 2005, Pages 5551-5558

  Ciaraldi, Theodore P ^a,b   Phillips, Susan A ^c   Carter, Leslie ^a,b   Aroda, Vanita ^a,b   Mudaliar, Sunder ^a,b   Henry, Robert R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLULISINE; INSULIN; INSULIN DERIVATIVE; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; SOMATOMEDIN C; THYMIDINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME PHOSPHORYLATION; FEMALE; GLUCOSE TRANSPORT; HORMONE BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BINDING; MALE; MUSCLE CELL; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE;

ADULT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DNA; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; MUSCLE, SKELETAL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYMIDINE;

EID: 26244432559     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1007     Document Type: Article

References (53)

1. Chakraborty C, Mungantiwar AA 2003 Human insulin genome sequence map, biochemical structure of insulin for recombinant DNA insulin. Mini Rev Med Chem 3:375-385
2. De Meyts P 2004 Insulin and its receptor: structure, function and evolution. Bioessays 26:1351-1362
3. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, Surface PL, Chance RE 1997 Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40(Suppl 2):S54-S61
4. Osterberg O, Erichsen L, Ingwersen SH, Plum A, Poulsen HE, Vicini P 2003 Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokin Pharmacodyan 30:221-235
5. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G 2003 Comparison of insulin aspart and lispro. Pharmacokinetic and metabolic effects. Diabetes Care 26:2027-2031
6. Lindholm A, Jacobsen LV 2001 Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 40:641-659
7. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Johnasses I, Schmid C, Trub T 2000 Correlations of receptor binding and metabolic and mitogenig potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005
8. Fawcett J, Hamel FG, Bennett RG, Vajo Z, Duckworth WC 2001 Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity. J Biol Chem 276:11552-11558
9. Somwar R, Sweeney G, Ramlal T, Klip A 1998 Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther 20:125-140
10. Vajo Z, Duckworth WC 2000 Genetically engineered insulin analogs: diabetes in the new millennium. Pharmacol Rev 52:1-9
11. Home PD, Ashwell SG 2002 An overview of insulin glargine. Diabetes Metab Res Rev 18:S57-S63
12. McKeage K, Goa KL 2001 Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and type 2 diabetes mellitus. Drugs 61:1599-1624
13. Virkamaki A, Ueki K, Kahn CR 1999 Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943
14. Entingh-Pearsall A, Kahn CR 2004 Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 279:38016-38024
15. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klien HH, Lundemose AG 1996 Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271-279
16. Shymko RM, Dumont E, De Meyts P, Dumonts JE 1999 Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 339:675-683
17. Kim S-J, Kahn CR 1997 Insulin regulation of mitogen-activated protein kinase kinase (MEK), mitogen-activated protein kinase and casein kinase in the cell nucleus: a possible role in the regulation of gene expression. Biochem J 323:621-627
18. Shi M, Feng YM 1997 Studies on growth-promoting action of insulin: mitogenic activity of insulin and its analogues in mouse mammary tumor cells. Biochem Mol Biol Int 43:705-711
19. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ 1991 Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal promoting activities. Diabetologia 34:307-313
20. Schwartz GP, Burke GT, Katsoyannis PG 1987 A superactive insulin: [B10-aspartic acid]insulin (human). Proc Natl Acad Sci USA 84:6408-6411
21. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J 2003 A novel insulin analog with unique properties. LysB3, GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227-2238
22. Rakatzi I, Seipke G, Eckel J 2003 [LysB3, GluB29] insulin: a novel insulin analog with enhanced β-cell protective action. Biochem Biophys Res Commun 310:852-859
23. Thornburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR 1990 Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522-529
24. Thornburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR 1991 Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 87:489-495
25. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP 1995 Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes 44:936-946
26. Ciaraldi TP, Abrams L, Nikoulina S, Mudaliar S, Henry RR 1995 Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 96:2820-2827
27. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 71:248-254
28. Berhanu P, Anderson C, Hickman M, Ciaraldi TP 1997 Insulin signal transduction by a mutant human insulin receptor lacking the NPEY sequence. J Biol Chem 272:22884-22890
29. Burnette WN 1981 "Western blotting" electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112:195-203
30. Ciaraldi TP, Carter L, Rehman N, Mohideen P, Mudaliar S, Henry RR 2002 Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. Metabolism 51:1171-1179
31. Hanada M, Feng J, Hemmings BA 2004 Structure, regulation and function of PKB/Akt: a major therapeutic target. Biochim Biophys Acta 1697:3-16
32. Pruett W, Yuan Y, Rose E, Batzer AG, Harada N, Skolnik EY 1995 Association between GRB2/SOS and insulin receptor substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by interlukin-4: implications for ras activation by insulin. Mol Cell Biol 15:1778-1785
33. Sasoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M 1996 Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 137:4427-4434
34. Gillies PS, Figgitt DP, Lamb HM 2000 Insulin glargine. Drugs 59:261-262
35. Peavy DE, Edmonson JW, Duckworth WC 1984 Selective effects of inhibitors of hormone processing on insulin action in isolated hepatocytes. Endocrinology 114:753-760
36. Duckworth WC, Bennett RG, Hamel FG 1998 Insulin acts intracellularly on proteasomes through insulin-degrading enzyme. Biochem Biophys Res Commun 244:390-394
37. Becker R, Frick A, Wessels D, Scholtz H 2003 Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine. Diabetes 52:A110
38. Barlocco D 2003 Insulin glulisine. Aventis Pharma. Curr Opin Invest Drugs 4:1240-1244
39. Hennige AM, Lehmann R, Weigert C, Moeschel K, Schauble M, Metzinger E, Lammers R, Haring H-U 2005 Insulin glulisine. Insulin receptor signaling characteristics in vivo. Diabetes 54:361-366
40. Kellerer M, Haring HU 2001 Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes 109:63-64
41. Gaster M, Petersen I, Hojlund K, Poulsen P, Beck-Nielsen H 2002 The diabetic phenotype is conserved in myotubes established from diabetic subjects: evidence for primary defects in glucose transport and glycogen synthase activity. Diabetes 51:921-927
42. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE 1996 Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. J Clin Invest 98:1231-1236
43. Nikoulina SE, Ciaraldi TP, Carter L, Mudaliar S, Park KS, Henry RR 2001 Impaired muscle glycogen synthase in type 2 diabetes is associated with diminished phosphatidylinositol 3-kinase activation. J Clin Endocrinol Metab 86:4307-4314
44. Krutzfeldt J, Kausch C, Volk A, Klein HH, Rett K, Haring HU, Stumvoll M 2000 Insulin signaling and action in cultured skeletal muscle cells from lean healthy humans with high and low insulin sensitivity. Diabetes 49:992-998
45. Bahr M, Kolter T, Seipke GJE 1997 Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265
46. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR 2001 Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86:5838-5847
47. Kim Y-B, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB 1999 Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741
48. Higaki Y, Wojtaszewski JFP, Hirshman MF, Withers DJ, Towery H, White MF, Goodyear LJ 1999 Insulin receptor substrate-2 is not necessary for insulin- and exercise-stimulated glucose transport in skeletal muscle. J Biol Chem 274:20791-20795
49. Sadagurski M, Weingarten G, Rhodes CJ, White MF, Wertheimer E 2005 Insulin receptor substrate 2 plays diverse cell-specific roles in the regulation of glucose transport. J Biol Chem 280:14536-14544
50. Huang C, Thirone AC, Huang X, Klip A 2005 Differential contribution of IRS-1 vs IRS-2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem 280
51. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren J-M, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF 1998 Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-904
52. Lingohr MK, Dickson LM, Wrede CE, Briaud I, McCuaig JF, Myers MGJ, Rhodes CJ 2003 Decreasing IRS-2 expression in pancreatic β-cells (INS-1) promotes apoptosis, which can be compensated for by introduction of IRS-4 expression. Mol Cell Endocrinol 209:17-31
53. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, Satoh S, Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, Nagai, R., Kimira S, Akanuma Y, Taylor SI, Kadowaki T 2000 Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory β-cell hyperplasia. Diabetes 49:1880-1889